REG - Hikma Pharmaceutical - Result of AGM
RNS Number : 4938WHikma Pharmaceuticals Plc23 April 2021
Hikma Pharmaceuticals PLC
Voting Results of 2021 Annual General Meeting
LONDON, 23 April 2021 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting ("AGM"), held at 1 New Burlington Place, W1S 2HR, London on 23 April 2021 commenced at 1:00 pm. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 15 and 17 were passed as ordinary resolutions and Resolutions 16 and 18 to 22 were passed as special resolutions.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the to the FCA's Electronic Submission System and will be available from the National Storage Mechanism.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 24 February 2021) is set out below. The number of Ordinary Shares in issue on 23 April 2021 was 243,604,637. There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 230,771,404.
Resolution
Votes For
%
Votes Against
%
Total Cast
Withheld
1. To receive the 2020 report and accounts
176,723,133
100.0
16,692
0
176,739,825
1,537,096
2. To approve a final dividend of 34 cents per share
178,275,824
100.0
152
0
178,275,976
945
3. To re-appoint PricewaterhouseCoopers LLP as auditors
177,053,202
99.3
1,222,474
0.7
178,275,676
1,245
4.To authorise the Audit Committee to determine the auditors' remuneration
178,174,755
99.9
100,365
0.1
178,275,120
1,801
5. To elect Douglas Hurt as a director
174,859,594
98.1
3,414,131
1.9
178,273,725
3,196
6. To re-elect Said Darwazah as a director
171,553,543
97.2
4,923,908
2.8
176,477,451
1,799,470
7. To re-elect Siggi Olafsson as a director
176,112,071
98.8
2,163,336
1.2
178,275,407
1,514
8. To re-elect Mazen Darwazah as a director
171,246,066
96.1
6,949,669
3.9
178,195,735
81,186
9. To re-elect Patrick Butler as a director
172,831,258
97.0
5,434,621
3.1
178,265,879
11,041
10.To re-elect Ali Al-Husry as a director
175,142,703
98.3
3,053,032
1.7
178,195,735
81,186
11. To re-elect Dr. Pamela Kirby as a director
167,790,753
95.1
8,655,778
4.9
176,446,531
1,830,390
12. To re-elect John Castellani as a director
175,101,327
98.9
1,975,760
1.1
177,077,087
1,199,834
13. To re-elect Nina Henderson as a director
175,403,863
98.4
2,871,070
1.6
178,274,933
1,988
14. To re-elect Cynthia Schwalm as a director
154,099,252
86.5
24,120,681
13.5
178,219,933
56,988
15. To approve the remuneration report for the year ended 31 December 2020
160,014,990
90.4
17,063,364
9.6
177,078,354
1,198,566
16. To approve the adoption of the new articles of association for the Company
177,680,870
99.7
593,294
0.3
178,274,164
2,757
17. Authority to allot shares
154,848,864
86.9
23,426,822
13.1
178,275,686
1,235
18. To dis-apply pre-emption rights for general purposes
177,563,944
99.6
711,824
0.4
178,275,768
1,153
19. To dis-apply pre-emption rights for an acquisition or other capital investment
174,606,709
97.9
3,668,585
2.1
178,275,294
1,627
20. To authorise the Company to purchase its own shares
176,712,127
99.2
1,480,842
0.8
178,192,969
83,952
21. To authorise the Company to hold general meetings on no less than 14 clear days' notice
169,544,820
95.1
8,731,027
4.9
178,275,847
1,074
Declaration of final dividend
The dividend of 34 cents per share will be paid on 26 April 2021 to shareholders on the register on 19 March 2021. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.3762998 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.709JD.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary
+44 20 7399 2670
Susan Ringdal
EVP, Strategic Planning and Global Affairs
+44 20 7399 2670
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDRAGSEUFLDEFSEDL
Recent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
Announcement